TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Area of Science:

• Cellular and Molecular Biology
• Gene Therapy
• Immunotherapy

Background:

• Gene therapy medicinal products (GTMPs) are increasingly used, yet detailed molecular characterization is limited.
• Chimeric antigen receptor (CAR) T-cell therapy highlights the need for understanding vector integrity and copy numbers in production.
• The TEG001 product, used in a first-in-human trial (NTR6541), requires precise molecular profiling.

Purpose of the Study:

• To perform detailed molecular characterization of the TEG001 gene-modified T-cell product.
• To assess insert integrity, vector copy number, and potential genetic variations in TEG001.
• To evaluate the safety profile regarding cellular proliferation and malignant transformation risk.

Main Methods:

• Targeted locus amplification combined with next-generation sequencing.
• Analysis of the vector producer clone and the final TEG001 product.
• In vitro culture to assess cellular proliferation and environmental risk assessment.

Main Results:

• Five single-nucleotide variants and nine intact vector copies were identified in the producer clone.
• TEG001 cells exhibited a vector copy number 0.72-fold that of the producer clone.
• Identified variants were transferred to TEG001 without affecting proliferation; no altered environmental impact was detected.

Conclusions:

• TEG001 cells possess defined molecular characteristics with stable insert integrity.
• The vector copy number is consistent and does not pose an immediate safety concern for proliferation.
• Environmental risk assessment indicates TEG001 does not present an increased risk for in vivo malignant transformation.